Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sarah Asby"'
Autor:
Sarah Asby, Erin Binne, Gannon Kehe, Pinky Kadur, Devika Dharmala, Michael Schurr, Chaitanya Puranik, Devatha P. Nair
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 90-91 (2023)
OBJECTIVES/GOALS: Our objective is to investigate the antibacterial and regenerative properties of a novel AHA dental coating for the prevention and treatment of deep caries (cavities). Further, we aim to investigate and compare these properties thro
Externí odkaz:
https://doaj.org/article/dc946acc305a4670b14531ca1615192a
Autor:
Patrick Innamarato, Jennifer Morse, Amy Mackay, Sarah Asby, Matthew Beatty, Jamie Blauvelt, Scott Kidd, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Chemotherapy regimens that include the utilization of gemcitabine are the standard of care in pancreatic cancer patients. However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even wh
Externí odkaz:
https://doaj.org/article/32e2ee001c5e4d209c02f66427128c37
Autor:
Jennifer Morse, Shari Pilon-Thomas, John Mullinax, Patrick Innamarato, Sarah Asby, Amy Mackay, Matthew Beatty, Jaime Blauvelt, Scott Kidd
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d9a4745eb5b944998635c03752c5ad69
Autor:
Jennifer Morse, Shari Pilon-Thomas, Patrick Innamarato, Sarah Asby, Matthew Beatty, Michael Poch, Brittany L Bunch, Jamie Blauvelt, Ahmet M Aydin, Ali Hajiran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The therapeutic armamentarium of bladder cancer has been recently enriched with the introduction of new therapies including immune checkpoint inhibitors, receptor tyrosine kinase inhibitors and antibody drug conjugates, however treatment r
Externí odkaz:
https://doaj.org/article/50a9c72270694fdd84eb11ba7aa1699d
Autor:
Matthew Beatty, Sarah Asby, Amod A. Sarnaik, Amy Mackay, John E. Mullinax, Patrick Innamarato, Shari Pilon-Thomas, Jennifer Morse, Jamie Blauvelt, Scott Kidd
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Background Chemotherapy regimens that include the utilization of gemcitabine are the standard of care in pancreatic cancer patients. However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even when treate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372ea380049ea1075410d9d58a89cf60
https://doi.org/10.1186/s12885-021-08522-z
https://doi.org/10.1186/s12885-021-08522-z
Autor:
Patrick Innamarato, Amy Mackay, Shari Pilon-Thomas, Jaime Blauvelt, Scott Kidd, John E. Mullinax, Jennifer Morse, Sarah Asby, Matthew Beatty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chemotherapy regimens that include gemcitabine are considered standard of care in patients with advanced pancreatic ductal adenocarcinoma (PDAC). However, most patients with PDAC die within 2 years of diagnosis, even with these standard of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f56a7a9e10ee7a64e53ad4f782b9d37
https://doi.org/10.1136/jitc-2020-sitc2020.0585
https://doi.org/10.1136/jitc-2020-sitc2020.0585
Autor:
MacLean Hall, Amy Mackay, Amod A. Sarnaik, Patrick Innamarato, Scott Kidd, Luz Nagle, Sarah Asby, Jennifer Morse, Shari Pilon-Thomas
Publikováno v:
J Immunol
The activation of 41BB costimulatory signals by agonistic Abs enhances the expansion and function of tumor-infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy. However, the impact of 41BB agonism is not limited to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c3cc6b93d93b24429848d4fd65f6dca
https://europepmc.org/articles/PMC7741883/
https://europepmc.org/articles/PMC7741883/
Autor:
Luz Nagle, Patrick Innamarato, Amod A. Sarnaik, MacLean Hall, Shari Pilon-Thomas, Doris Wiener, Ben C. Creelan, Matthew Beatty, Benjamin Schachner, Amy Mackay, Sarah Asby, Krithika Kodumudi
Publikováno v:
Mol Ther
Adoptive T cell therapy (ACT) in combination with lymphodepleting chemotherapy is an effective strategy to induce the eradication of tumors, providing long-term regression in cancer patients. Despite that lymphodepleting regimens condition the host f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811959a8ae2513f0f8c0ea5feecb2449
https://pubmed.ncbi.nlm.nih.gov/32615068
https://pubmed.ncbi.nlm.nih.gov/32615068
Autor:
Sarah Asby, Brittany L. Bunch, Jamie Blauvelt, Michael A. Poch, Matthew Beatty, Ali Hajiran, Shari Pilon-Thomas, Ahmet M. Aydin, Jennifer Morse, Patrick Innamarato
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe therapeutic armamentarium of bladder cancer has been recently enriched with the introduction of new therapies including immune checkpoint inhibitors, receptor tyrosine kinase inhibitors and antibody drug conjugates, however treatment re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0ce174e46fc4627c1ea488d2998180
https://doi.org/10.1136/jitc-2020-001673
https://doi.org/10.1136/jitc-2020-001673
Publikováno v:
Clinical Cancer Research. 26:A01-A01
Bladder cancer remains a leading cause of death and one of the most expensive cancers to treat in the United States. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) is a personalized therapeutic approach that has the potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1213251ef76973727fae8f28d700ff63
https://doi.org/10.1158/1557-3265.bladder19-a01
https://doi.org/10.1158/1557-3265.bladder19-a01